TrialCancer research and treatment2022

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.

Hye Ryeon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.